3.20
0.10 (3.23%)
| Penutupan Terdahulu | 3.10 |
| Buka | 2.98 |
| Jumlah Dagangan | 136,183 |
| Purata Dagangan (3B) | 276,354 |
| Modal Pasaran | 33,315,396 |
| Harga / Buku (P/B) | 1.15 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2025 - 11 Aug 2025 |
| Margin Operasi (TTM) | -11,193.25% |
| EPS Cair (TTM) | -3.70 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -62.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 31.69% |
| Nisbah Semasa (MRQ) | 1.69 |
| Aliran Tunai Operasi (OCF TTM) | -31.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -19.08 M |
| Pulangan Atas Aset (ROA TTM) | -48.28% |
| Pulangan Atas Ekuiti (ROE TTM) | -92.35% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | SAB Biotherapeutics, Inc. | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.88 |
|
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 21.02% |
| % Dimiliki oleh Institusi | 23.99% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| First Premier Bank | 30 Sep 2025 | 18,986 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 12.00 (Chardan Capital, 275.00%) | Beli |
| Median | 9.50 (196.88%) | |
| Rendah | 7.00 (Leerink Partners, 118.75%) | Beli |
| Purata | 9.50 (196.88%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 3.04 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Chardan Capital | 17 Nov 2025 | 12.00 (275.00%) | Beli | 3.50 |
| 19 Sep 2025 | 12.00 (275.00%) | Beli | 2.47 | |
| Leerink Partners | 17 Sep 2025 | 7.00 (118.75%) | Beli | 2.58 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 08 Dec 2025 | Pengumuman | SAB BIO to Present Data Showcasing Progress in the Development of SAB-142 at the Asian Conference on Innovative Therapies for Diabetes Management |
| 13 Nov 2025 | Pengumuman | SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights |
| 04 Nov 2025 | Pengumuman | SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142 |
| 04 Nov 2025 | Pengumuman | SAB BIO to Participate in Upcoming Investor Conferences |
| 19 Sep 2025 | Pengumuman | SAB BIO Highlights Data in Multiple Presentations at EASD |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |